Of particular interest, a number of first‐line chemotherapeutic drugs in CRC treatment, such as 5‐fluorouracil (5‐FU) and oxaliplatin, exert their therapeutic effects through causing damage to DNA.[45, 46] Targeting LIMp27 using Gapmer technology, nanoparticles loaded with LIMp27 siRNA, small molecule compounds, or small molecules that block the interaction of LIMp27 with hnRNPA0 all represent potential investigative avenues to advance our findings toward clinical applications.[47, 48, 49]. The gene discussed is HNRNPA0; the disease is colorectal carcinoma.